• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Vector Partners Limited

    Kyongbo Pharmaceutical

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Baxter BioPharma Solutions

    Vector Partners Limited

    Kyongbo Pharmaceutical

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Valneva Partners with UK Government for COVID-19 Vaccine

    UK secures supply of 60 million doses with options over another 130 million doses between 2022 and 2025.

    Valneva Partners with UK Government for COVID-19 Vaccine
    The UK government is investing up-front in the scale up and development of VLA2001.
    Related CONTENT
    • J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax
    • BioVaxys Reports Progress on Covid-19 Vax Candidate
    • CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    • Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    • UK Govt. Terminates Valneva COVID Vax Agreement
    Contract Pharma Staff09.16.20
    Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, has partnered with the UK government for its inactivated COVID-19 vaccine, VLA2001.
     
    Under the agreement, if vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021. The UK Government then has options over 40 million doses in 2022 and a further 30 million to 90 million doses, in aggregate, across 2023 to 2025. Revenue from these options could amount to almost €900 million ($1.1 billion).
     
    The UK government is also investing up-front in the scale up and development of the vaccine, with the investment being recouped against the vaccine supply under the partnership. The agreement follows the initial intent to participate in the UK Government’s COVID-19 vaccine response announced in July.
     
    The Vaccine Candidate
     
    Valneva’s vaccine candidate, VLA2001, is based on a proven approach and will leverage the company’s existing manufacturing platform being used for its US FDA and EMA approved Japanese Encephalitis (JE) vaccine. VLA2001 is expected to enter clinical studies at the end of 2020 and, if the clinical development is successful, a first regulatory approval may be granted in the second half of 2021. 
     
    “Our proven track record and manufacturing capability in Scotland underpins this partnership. Through our recent discussions we’ve built a great working relationship with UK Government. I’d like to acknowledge the contributions of UK government task force and colleagues as well as other stakeholders including West Lothian, Scottish and UK politicians who are supporting the ongoing work. We see a fantastic spirit across all stakeholders to make this partnership succeed,” said David Lawrence, chief financial officer of Valneva.
     
    Thomas Lingelbach, CEO of Valneva, commented, “We made the early decision to choose a proven and well-established inactivated vaccine approach which is further validated by this partnership. We are honored to have been chosen by the UK Government and are eager to partner with them to address this terrible ongoing pandemic. This is another transformational step for Valneva following the Lyme partnership we signed earlier this year and our chikungunya vaccine commencing Phase 3 clinical studies last week. ”
     
    Valneva had previously announced an agreement in principle with the UK government for the supply of vaccine doses and a binding preliminary agreement to support expansion of its UK-based manufacturing facilities.
    Related Searches
    • blow fill seal
    • Phase II
    • manufacturing execution system (mes)
    • rfid
    Suggested For You
    J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax
    BioVaxys Reports Progress on Covid-19 Vax Candidate BioVaxys Reports Progress on Covid-19 Vax Candidate
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    UK Govt. Terminates Valneva COVID Vax Agreement UK Govt. Terminates Valneva COVID Vax Agreement
    Gaston Salinas Botanical Solution Inc. Gaston Salinas Botanical Solution Inc.
    Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
    Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines Pfizer, BioNTech Collaborate with Brazil’s Eurofarma to Manufacture Covid-19 Vaccines
    J&J Releases COVID-Vax Booster Data J&J Releases COVID-Vax Booster Data
    FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY FDA Approves Pfizer-BioNTech COVID-19 Vaccine COMIRNATY
    J&J CEO Alex Gorsky to Step Aside J&J CEO Alex Gorsky to Step Aside
    FDA Amends EUAs for COVID-19 Vaccines FDA Amends EUAs for COVID-19 Vaccines
    BioNTech’s 2Q Revenue Soars BioNTech’s 2Q Revenue Soars
    A Look Into COVID Vaccines, Development and Outsourcing A Look Into COVID Vaccines, Development and Outsourcing
    Pfizer Pfizer's 2Q Revenues Up 92%

    Related Content

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax

      J&J Data Confirms Strong and Long-Lasting Protection of COVID-19 Vax

      Phase 3 ENSEMBLE trial shows booster shot at two months provided 94 percent protection against COVID-19 in the U.S.
      09.21.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News | Parenterals
      BioVaxys Reports Progress on Covid-19 Vax Candidate

      BioVaxys Reports Progress on Covid-19 Vax Candidate

      Bioproduction partner Wuxi Biologics completes synthesis of recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH programs.
      09.16.21

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Gaston Salinas, Botanical Solution Inc.

      CEO Spotlight: Gaston Salinas, Botanical Solution Inc.

      QS-21 has become the ‘Gold Standard’ for human vaccine adjuvants and BSI is positioned to become a reliable supplier to the pharmaceutical market.
      Tim Wright, Editor, Contract Pharma 09.14.21


    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
      Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership

      Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership

      Ink multi-year development and manufacturing agreement for mRNA COVID-19 vaccine candidate, PTX-COVID19-B.
      09.14.21

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      UK Govt. Terminates Valneva COVID Vax Agreement

      UK Govt. Terminates Valneva COVID Vax Agreement

      Valneva is continuing its VLA2001 development plan with Phase III results expected 4Q21 and potential MHRA approval in late 2021.
      09.13.21

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • DFE Pharma Opens India CoE to Provide Fast-Track Formulation Services
      • Helsinn Establishes New R&D Hub in the U.S.
      • CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Brian Case Appointed Chief Technology Officer at KORU Medical
      Solid Growth Expected for India's Medical Device Sector
      Hologic Gains CE Mark for 2 Molecular Assays for Transplant Patients
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      Thayers Natural Remedies Celebrates 175 Years with Social Campaign
      Former Model Shirley Powell’s Indie Beauty Brand LaJeanell Comprises Gender Inclusive Skincare and Makeup
      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      Ink World

      Latest Breaking News From Ink World

      NAPIM’s Virtual Digital & Emerging Technologies Conference is Back, June 14–15, 2022
      CEMATEX Introduces Online Business Platform to Connect Global Textile Community
      PICO Chemical Celebrates 46 Years
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      ams OSRAM Introduces New Horticulture LEDs
      Avery Dennison Launches AD Twist U7XM Inlays
      ARPA-E Funding Drives Innovation, Industry Partnerships at NREL

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login